Longevity Science — April 4, 2026
This week's longevity science landscape is shaped by a growing debate over whether aging should be classified as a treatable disease, fresh industry data projecting 2026 as a breakout year for longevity biotech investment, and continued scrutiny of AI's expanding role in drug discovery. Early brain screening, bioprinted organs, and human senolytic trials are generating headlines, while new surveys reveal that most Americans still fundamentally misunderstand what drives longevity.
9 min read/15 sources
